ArticleCancers2022

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Fulvio Massaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.